ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

Despite the recent drag in Acadia Healthcare's (ACHC) business volumes, the same is expected to bounce back, given the defensive demand for its mental and behavioral health business.

Why Should You Hold onto Acadia Healthcare Stock?

The U.S and global demographic trends are favorably impacting the company’s operations.

ACADIA: The Company's Perspectives In Numbers.

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact.

ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q1 2020 Results - Earnings Call Transcript

Allogene Therapeutics Inc

Alnylam Pharmaceuticals

Alexion Pharma

Horizon Pharma

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Amedisys

Biogen

Boyd Gaming

Hill-Rom Hlds

Royal Caribbean Cruises

Teladoc

Thor Industries

UnitedHealth Group

Ventas

Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.

10 Stocks to Buy for an Aging Population

Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report?

Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.

This 1 Stock Is a Good Buy During the Coronavirus Sell-Off

Amarin Corporation Plc

Exact Sciences

Exelixis

Jazz Pharmaceuticals

Seagen

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

6 Quality Biotech Stocks on Sale Now

ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript

Acadia Pharmaceuticals: Undervalued And Ripe For A Major Run-Up

CRISPR Therapeutics

Acadia Pharmaceuticals and CRISPR Therapeutics both trounced the market last year. Here's why that could continue.

2 Biotech Stocks to Watch In 2020

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

ABIOMED

Accelerate Diagnostics

DexCom

Neurocrine Biosciences

NeoGenomics

Repligen

Simulations Plus

The 10 Best Healthcare Stocks of the Decade

Axsome Therapeutics

Acadia Pharmaceuticals and Axsome Therapeutics are top buyout candidates heading into the new year.

2 Biotech Stocks Poised to Soar in 2020

Is  (ACAD) Outperforming Other Medical Stocks This Year?

Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?

uniQure

Here are the biotechs most likely to receive juicy buyout offers in 2020.

3 Stocks That Could Be the Next Biotech Buyouts

Acadia's Steep Dive Lower Was More About Sourcing Liquidity

Anika Therapeutics

Gilead Sciences

Incyte

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Compugen

Cue Biopharma

Epizyme

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

5 Biotech Stocks That Have More Than Doubled This Year

Karuna Therapeutics Inc

Minerva Neurosciences

4 Biotech Neurology Stocks, As Biotechs March On

Proteostasis Therapeutics

In the case of PTI and ACAD, their greater upside potential earlier this month won out.

News for ACADIA Pharma Stock (ACAD)